CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| University of California, Los Angeles |
Song Li |
Conference II |
The 18th Annual UC System-Wide Bioengineering Symposium |
$25,000 |
| JDRF International |
JDRF Esther Latres |
Conference II |
JDRF Encapsulation Consortium Fall 2017 Meeting |
$42,425 |
| Stanford University |
Dr. Samuel Strober |
Conference II |
Third International Workshop on Clinical Tolerance |
$29,500 |
| American Association of Blood Banks |
Dr. Naynesh R. Kamani |
Conference II |
15th International Cord Blood Sympsium |
$30,000 |
| Stanford University |
Dr. Joseph C. Wu |
Conference II |
2017 Stanford Drug Discovery and Stem Cell Technology Conference |
$2,359 |
| University of Southern California |
Dr. Justin K Ichida |
Conference II |
The 7th Annual California ALS research network and PAC10 meeting |
$10,830 |
| Vitalant Research Institute |
Shibani Pati |
Conference II |
Cellular Therapies and Transfusion Medicine in Trauma and Critical Care – Looking Towards the Future |
$30,000 |
| University of California, San Diego |
Dr. Robert Lie-Yuan Sah |
Conference II |
2016 Tissue Engineering and Regenerative Medicine International Society – Americas (TERMIS-AM) Conference in San Diego, CA on December 11-14, 2016 |
$40,000 |
| Midwinter Conference of Immunologists |
Dr. Christel H. Uittenbogaart |
Conference II |
The 2017 Midwinter Conference of Immunologists at Asilomar |
$5,000 |
| Alliance Forum Foundation |
George Hara |
Conference II |
2016 World Alliance Forum in San Francisco (WAFSF) “US-Japan Innovative Healthcare Technologies Conference” |
$20,000 |
| University of California, Irvine |
Dr. Leslie M Thompson |
Conference II |
HD-CARE INAUGURAL SYMPOSIUM |
$1,500 |
| Keystone Symposia on Molecular and Cellular Biology |
Thale Jarvis |
Conference II |
Neurogenesis during Development and in the Adult Brain (joint with Transcriptional and Epigenetic Control in Stem Cells) |
$35,000 |
| American Association of Blood Banks |
Dr. Naynesh R. Kamani |
Conference II |
14th International Cord Blood Symposium: Give Life Twice |
$15,000 |
| University of California, San Diego |
Prof. John M. Ravits |
Conference II |
California ALS Research Summit 2016 |
$11,400 |
| Stanford University |
Dr. Joseph C. Wu |
Conference II |
Drug Discovery & Stem Cell Models for Cardiovascular Disease Conference |
$7,500 |
| Gordon Research Conferences |
Dr. Ophir Klein MD, PhD |
Conference II |
2016 Gordon Research Conference on Craniofacial Morphogenesis and Tissue Regeneration |
$5,000 |
| City of Hope, Beckman Research Institute |
Fouad R Kandeel |
Conference II |
2016 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium |
$10,000 |
| International Society for Experimental Hematology |
Dr. David Traver |
Conference II |
International Society for Experimental Hematology, 45th Annual Scientific Meeting |
$25,000 |
| University of California, Los Angeles |
Dr. Donald B. Kohn |
Conference II |
Primary Immune Deficiency Treatment Consortium (PIDTC) Annual Scientific Workshop |
$29,807 |
| Alliance Forum Foundation |
George Hara |
Conference II |
2015 World Alliance Forum in San Francisco (2015 WAFSF) “Regenerative Medicine: Let’s Talk Business!” |
$10,000 |
| Sanford Consortium for Regenerative Medicine |
Dr. Edward Holmes |
Conference II |
Stem Cell Meeting on the Mesa |
$50,000 |
| University of California, Irvine |
Dr. Sidney Golub |
Conference II |
Human Research In Times of Controversy: From Stem Cells To Fetal Tissue |
$13,562 |
| FOXG1 Research Foundation |
Gai Ayalon |
Clinical Trial Stage Projects |
Phase 1/ 2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients with FOXG1 Syndrome (FS) |
$4,928,664 |
| Tr1X Inc. |
Marco Londei |
Clinical Trial Stage Projects |
A Phase 1/2a First-in-Human, Dose-Escalation Study to Evaluate TRX319 in Subjects with Progressive Multiple Sclerosis |
$8,000,000 |
| Siren Biotechnology, Inc. |
Dr Nicole K Paulk |
Clinical Trial Stage Projects |
SRN-101 AAV Immuno-Gene Therapy for High-Grade Glioma |
$7,999,774 |
| Cellio Therapeutics |
Steven Schwartz |
Clinical Trial Stage Projects |
Autologous iPSC-derived Retinal Pigment Epithelium Cell Therapy to Restore Vision in Blinding Eye Disease |
$8,000,000 |
| Immusoft of CA, Inc. |
Dr Robert Hayes |
Clinical Trial Stage Projects |
Advancing ISP-001 for Mucopolysaccharidosis I: Clinical Expansion, Clinical Manufacturing and Release Testing |
$15,000,000 |
| Mahzi Therapeutics |
Dr. Yael Weiss |
Clinical Trial Stage Projects |
Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of MZ-1866, a gene therapy for Pitt Hopkins Syndrome |
$8,000,000 |
| Kenai Therapeutics |
Howard J Federoff |
Clinical Trial Stage Projects |
A Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease |
$8,000,000 |
| Elpida Therapeutics |
Dr. Keith Gottlieb |
Clinical Trial Stage Projects |
Phase I/II Clinical Trial for CMT4J |
$8,000,000 |
| Encoded Therapeutics |
Salvador Rico |
Clinical Trial Stage Projects |
Clinical Development of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome |
$0 |
| University of California, Irvine |
Dr. Leslie M Thompson |
Clinical Trial Stage Projects |
Phase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD) |
$10,469,013 |
| Neurona Therapeutics |
Dr. Cory R Nicholas |
Clinical Trial Stage Projects |
Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy |
$13,999,983 |
| University of California, San Francisco |
Dr Morton Cowan |
Clinical Trial Stage Projects |
Gene Therapy for Artemis-Deficient Severe Combined Immunodeficiency Using a Self-Inactivating Lentiviral Vector |
$14,999,999 |
| Ray Therapeutics, INC |
Paul Bresge |
Clinical Trial Stage Projects |
Optogenetic Gene Therapy for Treatment of Retinitis Pigmentosa |
$7,975,224 |
| Tenaya Therapeutics, Inc. |
Dr. Matthew Pollman |
Clinical Trial Stage Projects |
Phase 1b Study of TN-401 in Adults with PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) |
$8,000,000 |
| Tr1X Inc. |
Maria Grazia Roncarolo |
Clinical Trial Stage Projects |
TRX103 for prevention of GvHD in patients receiving HLA mismatched HSCT for the treatment of hematologic malignancies |
$8,000,000 |
| University of California, Los Angeles |
Dr. Donald B. Kohn |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS-ADA lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$14,325,181 |
| Fate Therapeutics, Inc. |
Dr. Vaneet Sandhu |
Clinical Trial Stage Projects |
A Phase 1 Study of FT819 in Participants with Moderate to Severe Active Systemic Lupus Erythematosus |
$7,934,448 |
| Senti Biosciences, Inc. |
Rochelle Emery |
Clinical Trial Stage Projects |
Selective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies |
$8,000,000 |
| ImmPACT-Bio, Inc. |
Dr. Jonathan Benjamin |
Clinical Trial Stage Projects |
A phase 1/2 study to evaluate a bispecific CD19/CD20-directed CAR T cell, in refractory lupus nephritis and systemic lupus erythematosus |
$841,214 |
| Nexcella, Inc. |
Ilya Rachman MD PhD |
Clinical Trial Stage Projects |
Autologous BCMA CAR-T Cells for the Treatment of Relapsed Refractory Light Chain Amyloidosis |
$7,999,467 |
| University of California, San Francisco |
Dr. Hideho Okada |
Clinical Trial Stage Projects |
Phase 1 Study of Autologous E-SYNC T Cells in Adult Participants with EGFRvIII+ Glioblastoma |
$10,927,618 |
| Aspen Neuroscience |
Dr. Edward Wirth III |
Clinical Trial Stage Projects |
Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease |
$8,000,000 |
| Alto Neuroscience |
Amit Etkin |
Clinical Trial Stage Projects |
A Phase 2b Study of the Efficacy of a Novel Pro-Neurogenesis/Pro-Plasticity Drug for Bipolar Depression Using a Precision Psychiatry Approach |
$0 |
| Allogene Therapeutics |
Zachary J. Roberts |
Clinical Trial Stage Projects |
A PHASE 1B STUDY EVALUATING THE SAFETY AND EFFICACY OF AN ALLOGENEIC CELL THERAPY IN SUBJECTS WITH CLEAR CELL RENAL CELL CARCINOMA (ccRCC) |
$9,238,404 |
| University of California, San Francisco |
Noriyuki Kasahara |
Clinical Trial Stage Projects |
A Phase I/IIa Study to Evaluate the Efficacy of Toca 511/Toca FC with Standard of Care Therapy in Newly Diagnosed High Grade Glioma |
$11,807,220 |
| Luxa Biotechnology |
Dr. Jeffrey H Stern |
Clinical Trial Stage Projects |
RPESC-RPE-4W Therapy for dry Age-related Macular Degeneration |
$4,009,675 |
| Rocket Pharmaceuticals, Inc. |
Dr. Jonathan Schwartz |
Clinical Trial Stage Projects |
A Phase 2 Study Evaluating the Efficacy and Safety of IV Administered rAAV9 Vector Containing RP-A501 in Male Patients with Danon Disease |
$5,808,735 |
| University of California, Davis |
Dr. Diana L. Farmer |
Clinical Trial Stage Projects |
The CuRe Trial: Cellular Therapy for In Utero Repair of Myelomeningocele |
$8,996,477 |
